Evidence map›Paper›PMID 37787975›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer.

Erica S Tsang, Steven Gallinger

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Erica S TsangPrincess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0003-2317-2721
Steven GallingerOntario Institute for Cancer Research, Toronto, Ontario, Canada.ORCID 0000-0002-6998-9414
Ontario Institute for Cancer Research · CAPrincess Margaret Cancer Centre · CA

Funding

Ontario Institute for Cancer Research (OICR)
6 · The paper itself

Abstract

A recent article analyzed paired cell-free DNA among patients with platinum-sensitive BRCA- or PALB2-mutated pancreatic cancer who received maintenance olaparib. Reversion mutations were linked with worse outcomes. These types of paired correlative studies are needed to improve our understanding of drug resistance and guide future clinical trials. See related article by Brown et al., p. 5207.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsPancreatic NeoplasmsBRCA2 ProteinFemaleHumansPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsBRCA2 ProteinPhthalazinesPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID37787975
OpenAlexW4387297143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.